Weight loss drug side effects compared: nausea, GI issues, and quit rates

Last reviewed: June 2026Based on 3 clinical trialsEvery claim linked to source

Quick read · 6 min

Nausea is the #1 reason people worry about starting weight loss medication — and the #1 reason some people stop. Here is exactly how the three newest drugs compare, using data from their largest clinical trials.

93%
stayed on Wegovy
(7% quit from side effects)
94%
stayed on Zepbound
(6% quit from side effects)
92%
stayed on Foundayo
(8% quit from side effects)

Side-by-side: how the three drugs compare

Each percentage below represents the share of trial participants who experienced that side effect at any point during the study. Higher bars mean more people were affected.

Nausea
Wegovy
44%
Zepbound
31%
Foundayo
33%
Vomiting
Wegovy
24%
Zepbound
18%
Foundayo
19%
Diarrhoea
Wegovy
30%
Zepbound
23%
Foundayo
15%
Constipation
Wegovy
24%
Zepbound
12%
Foundayo
18%
Fatigue
Wegovy
11%
Zepbound
7%
Foundayo
6%
Indigestion
Wegovy
9%
Zepbound
10%
Foundayo
10%
✓ Zepbound: Lowest nausea in trials (31%)
✓ Foundayo: Lowest diarrhoea in trials (15%)
✓ Zepbound: Lowest quit rate in trials (6%)
Key insight
In these clinical trials, tirzepatide (Zepbound) showed the lowest rates for the most bothersome side effects — nausea, vomiting, and diarrhoea. The differences between tirzepatide and orforglipron are small (1–2 percentage points for nausea and vomiting). The bigger gap is between these two and semaglutide, which showed notably higher nausea (44%) and diarrhoea (30%) in trial data.

When do side effects peak? A typical timeline

Side effects are not constant. They follow a predictable pattern tied to dose increases:

Weeks 1–2
Starting dose — mildest

Most people start at the lowest dose. Nausea affects roughly 1 in 3 people, usually mild. The body is adjusting.

Weeks 3–8
Dose increases — worst window

Each dose increase can trigger a new wave of nausea. This is the period when most people feel the worst. It usually passes within 3–5 days per increase.

Weeks 8–16
Settling down

For most people, GI side effects become significantly milder or disappear entirely as the body adapts to the maintenance dose.

Week 16+
Maintenance — steady state

The majority of people who stayed through the adjustment period report minimal or no ongoing GI issues.

How to reduce side effects

🍽️
Eat smaller, more frequent meals
Large meals overwhelm a slower-emptying stomach. 4–5 small meals instead of 2–3 large ones makes a significant difference.
🚫
Avoid fatty and fried foods
High-fat meals sit in the stomach longer and are the most common nausea trigger. Lean protein and vegetables are easier to tolerate.
🐢
Eat slowly
Eating too fast before your brain registers fullness is the top cause of post-meal nausea. Take 20+ minutes per meal.
💧
Stay hydrated
Sip water throughout the day. Dehydration worsens nausea and is common when appetite is reduced and you are eating less food.
⏰
Consistent timing
Take your medication at the same time each week (injections) or day (pills). Consistency helps the body adapt.
📈
Slow titration
Stay at each dose for the full 4 weeks before increasing. If side effects are severe, your doctor can extend the titration period.

Full side effect profiles

Semaglutide (Wegovy)

Weekly injection
STEP 1 · 1,961 participants
Nausea44%
Vomiting24%
Diarrhoea30%
Constipation24%
Abdominal pain20%
Fatigue11%
Indigestion9%
Stayed on medication93%
Quit due to side effects7%

Tirzepatide (Zepbound)

Weekly injection
SURMOUNT-1 · 2,539 participants
Nausea31%
Vomiting18%
Diarrhoea23%
Constipation12%
Abdominal pain9%
Fatigue7%
Indigestion10%
Stayed on medication94%
Quit due to side effects6%

Orforglipron (Foundayo)

Daily pill
ATTAIN-1 · 989 participants
Nausea33%
Vomiting19%
Diarrhoea15%
Constipation18%
Fatigue6%
Indigestion10%
Stayed on medication92%
Quit due to side effects8%

Bottom line

In clinical trials, tirzepatide (Zepbound) had the lowest GI side effect rates and the lowest quit rate (6%). Orforglipron (Foundayo) fell in the middle — similar nausea to tirzepatide but the lowest diarrhoea rate of the three. Semaglutide (Wegovy) had higher nausea and diarrhoea rates, though over 93% of participants still stayed on medication. For all three drugs, side effects typically peak during dose increases and resolve by weeks 12–16.

Next step most people take

Compare all options side by side
GLP-1 nausea — the full deep dive
Muscle loss comparison

Built with agentic AI tools and not a substitute for medical advice

Last reviewed: June 2026

Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.